{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:13:16Z","timestamp":1790903596546,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wellcome Trust Clinical PhD Fellowship","award":["105392\/B\/14\/Z"],"award-info":[{"award-number":["105392\/B\/14\/Z"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Further work is required to understand the intrapulmonary pharmacokinetics of first-line anti-tuberculosis drugs. This study aimed to describe the plasma and intrapulmonary pharmacokinetics of rifampicin, isoniazid, pyrazinamide, and ethambutol, and explore relationships with clinical treatment outcomes in patients with pulmonary tuberculosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Malawian adults with a first presentation of microbiologically confirmed pulmonary tuberculosis received standard 6-month first-line therapy. Plasma and intrapulmonary samples were collected 8 and 16 weeks into treatment and drug concentrations measured in plasma, lung\/airway epithelial lining fluid (ELF), and alveolar cells. Population pharmacokinetic modeling generated estimates of drug exposure (Cmax and AUC) from individual-level post hoc Bayesian estimates of plasma and intrapulmonary pharmacokinetics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One-hundred fifty-seven patients (58% HIV coinfected) participated. Despite standard weight-based dosing, peak plasma concentrations of first-line drugs were below therapeutic drug-monitoring targets. Rifampicin concentrations were low in all 3 compartments. Isoniazid, pyrazinamide, and ethambutol achieved higher concentrations in ELF and alveolar cells than plasma. Isoniazid and pyrazinamide concentrations were 14.6-fold (95% CI, 11.2\u201318.0-fold) and 49.8-fold (95% CI, 34.2\u201365.3-fold) higher in ELF than plasma, respectively. Ethambutol concentrations were highest in alveolar cells (alveolar cell\u2013plasma ratio, 15.0; 95% CI, 11.4\u201318.6). Plasma or intrapulmonary pharmacokinetics did not predict clinical treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We report differential drug concentrations between plasma and the lung. While plasma concentrations were below therapeutic monitoring targets, accumulation of drugs at the site of disease may explain the success of the first-line regimen. The low rifampicin concentrations observed in all compartments lend strong support for ongoing clinical trials of high-dose rifampicin regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1265","type":"journal-article","created":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T15:27:29Z","timestamp":1598282849000},"page":"e3365-e3373","source":"Crossref","is-referenced-by-count":20,"title":["Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0814-3834","authenticated-orcid":false,"given":"Andrew D","family":"McCallum","sequence":"first","affiliation":[{"name":"Malawi-Liverpool-Wellcome Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi"},{"name":"Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom"},{"name":"Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry E","family":"Pertinez","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J","family":"Else","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujan","family":"Dilly-Penchala","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P","family":"Chirambo","sequence":"additional","affiliation":[{"name":"Malawi-Liverpool-Wellcome Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Sheha","sequence":"additional","affiliation":[{"name":"Malawi-Liverpool-Wellcome Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalitso","family":"Chasweka","sequence":"additional","affiliation":[{"name":"Malawi-Liverpool-Wellcome Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Chitani","sequence":"additional","affiliation":[{"name":"Malawi-Liverpool-Wellcome Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose D","family":"Malamba","sequence":"additional","affiliation":[{"name":"Malawi-Liverpool-Wellcome Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamilah Z","family":"Meghji","sequence":"additional","affiliation":[{"name":"Malawi-Liverpool-Wellcome Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi"},{"name":"Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B","family":"Gordon","sequence":"additional","affiliation":[{"name":"Malawi-Liverpool-Wellcome Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi"},{"name":"Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraint R","family":"Davies","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saye H","family":"Khoo","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J","family":"Sloan","sequence":"additional","affiliation":[{"name":"School of Medicine, University of St Andrews, St Andrews, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry C","family":"Mwandumba","sequence":"additional","affiliation":[{"name":"Malawi-Liverpool-Wellcome Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi"},{"name":"Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"2021110300153700800_CIT0001","volume-title":"Global tuberculosis","author":"World Health Organization.","year":"2019"},{"key":"2021110300153700800_CIT0002","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2125.2011.03940.x","article-title":"Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients","volume":"72","author":"Wilkins","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"2021110300153700800_CIT0003","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1128\/AAC.00274-11","article-title":"Population pharmacokinetics of ethambutol in South African tuberculosis patients","volume":"55","author":"J\u00f6nsson","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2021110300153700800_CIT0004","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1128\/AAC.00461-07","article-title":"Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption","volume":"52","author":"Wilkins","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2021110300153700800_CIT0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00228-006-0141-z","article-title":"Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients","volume":"62","author":"Wilkins","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"2021110300153700800_CIT0006","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/cid\/ciw471","article-title":"Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests","volume":"63","author":"Swaminathan","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021110300153700800_CIT0007","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"key":"2021110300153700800_CIT0008","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1128\/AAC.03931-14","article-title":"Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis","volume":"59","author":"Chigutsa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021110300153700800_CIT0009","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1093\/cid\/cix158","article-title":"Concentration-dependent antagonism and culture conversion in pulmonary tuberculosis","volume":"64","author":"Rockwood","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021110300153700800_CIT0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4155\/ipk-2017-0004","article-title":"The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes","volume":"2","author":"McCallum","year":"2017","journal-title":"Int J Pharmacokinet"},{"key":"2021110300153700800_CIT0011","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/nm.3937","article-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions","volume":"21","author":"Prideaux","year":"2015","journal-title":"Nat Med"},{"key":"2021110300153700800_CIT0012","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1164\/rccm.201711-2333OC","article-title":"Drug-penetration gradients associated with acquired drug resistance in patients with tuberculosis","volume":"198","author":"Dheda","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2021110300153700800_CIT0013","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11592900-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"2021110300153700800_CIT0014","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/11594090-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"2021110300153700800_CIT0015","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1128\/AAC.00712-11","article-title":"Penetration of vancomycin into epithelial lining fluid in healthy volunteers","volume":"55","author":"Lodise","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2021110300153700800_CIT0016","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/01.CCM.0000168206.59873.80","article-title":"Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia","volume":"33","author":"Boselli","year":"2005","journal-title":"Crit Care Med"},{"key":"2021110300153700800_CIT0017","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2165\/00003088-200443060-00003","article-title":"Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin","volume":"43","author":"Conte","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"2021110300153700800_CIT0018","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1128\/AAC.46.8.2358-2364.2002","article-title":"Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid","volume":"46","author":"Conte","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2021110300153700800_CIT0019","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1128\/AAC.43.6.1329","article-title":"Intrapulmonary concentrations of pyrazinamide","volume":"43","author":"Conte","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2021110300153700800_CIT0020","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1128\/AAC.45.10.2891-2896.2001","article-title":"Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations","volume":"45","author":"Conte","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2021110300153700800_CIT0021","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/jac\/dkf214","article-title":"Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy","volume":"50","author":"Ziglam","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2021110300153700800_CIT0022","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jtbi.2011.05.013","article-title":"Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin","volume":"282","author":"Goutelle","year":"2011","journal-title":"J Theor Biol"},{"key":"2021110300153700800_CIT0023","doi-asserted-by":"crossref","DOI":"10.3791\/4345","article-title":"Bronchoalveolar lavage (BAL) for research; obtaining adequate sample yield","author":"Collins","year":"2014","journal-title":"J Vis Exp"},{"key":"2021110300153700800_CIT0024","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/thx.2010.136242","article-title":"A simple, valid, numerical score for grading chest X-ray severity in adult smear-positive pulmonary tuberculosis","volume":"65","author":"Ralph","year":"2010","journal-title":"Thorax"},{"key":"2021110300153700800_CIT0025","volume-title":"National tuberculosis control programme manual","author":"Ministry of Health Malawi.","year":"2012","edition":"7th ed."},{"key":"2021110300153700800_CIT0026","volume-title":"Clinical management of HIV in children and adults","author":"Ministry of Health Malawi.","year":"2014"},{"key":"2021110300153700800_CIT0027","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00133-06","article-title":"Interpretation of antibiotic concentration ratios measured in epithelial lining fluid","volume":"52","author":"Kiem","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2021110300153700800_CIT0028","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1183\/09031936.96.09071381","article-title":"Alveolar epithelial lining fluid cellularity, protein and endothelin-1 in children with congenital heart disease","volume":"9","author":"Grigg","year":"1996","journal-title":"Eur Respir J"},{"key":"2021110300153700800_CIT0029","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"key":"2021110300153700800_CIT0030","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1086\/599040","article-title":"Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana","volume":"48","author":"Chideya","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2021110300153700800_CIT0031","volume-title":"Guidelines for treatment of tuberculosis","author":"World Health Organization","year":"2010"},{"key":"2021110300153700800_CIT0032","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/jac\/dkp262","article-title":"Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis","volume":"64","author":"Sch\u00f6n","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2021110300153700800_CIT0033","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dky152","article-title":"Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis","author":"Stott","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021110300153700800_CIT0034","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1128\/AAC.01193-15","article-title":"Pharmacokinetics of antituberculosis drugs in HIV-positive and HIV-negative adults in Malawi","volume":"59","author":"van Oosterhout","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021110300153700800_CIT0035","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1128\/AAC.50.4.1170-1177.2006","article-title":"Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients","volume":"50","author":"McIlleron","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2021110300153700800_CIT0036","doi-asserted-by":"crossref","first-page":"e0141002","DOI":"10.1371\/journal.pone.0141002","article-title":"Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania","volume":"10","author":"Denti","year":"2015","journal-title":"PLoS One"},{"key":"2021110300153700800_CIT0037","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1128\/AAC.01681-08","article-title":"Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs","volume":"53","author":"Gumbo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2021110300153700800_CIT0038","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1128\/AAC.00185-07","article-title":"Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2021110300153700800_CIT0039","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2021110300153700800_CIT0040","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1086\/651377","article-title":"Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol","volume":"201","author":"Srivastava","year":"2010","journal-title":"J Infect Dis"},{"key":"2021110300153700800_CIT0041","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","article-title":"A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis","volume":"191","author":"Boeree","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2021110300153700800_CIT0042","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/infdis\/jiy242","article-title":"Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations","volume":"218","author":"Svensson","year":"2018","journal-title":"J Infect Dis"},{"key":"2021110300153700800_CIT0043","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1128\/AAC.02307-13","article-title":"Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV","volume":"58","author":"Jeremiah","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021110300153700800_CIT0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/civ195","article-title":"Pharmacodynamic modeling of bacillary elimination rates and detection of bacterial lipid bodies in sputum to predict and understand outcomes in treatment of pulmonary tuberculosis","volume":"61","author":"Sloan","year":"2015","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1265\/34788540\/ciaa1265.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/9\/e3365\/41060740\/ciaa1265.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/9\/e3365\/41060740\/ciaa1265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T20:18:05Z","timestamp":1635884285000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/9\/e3365\/5898506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,8,28]]},"published-print":{"date-parts":[[2021,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1265","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2020,8,28]]}}}